Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials

[1]  A. Kastrati,et al.  Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention. , 2008, European heart journal.

[2]  E. Antman,et al.  Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38). , 2006, American heart journal.

[3]  T. Heer,et al.  Comparison of clinical benefits of clopidogrel therapy in patients with acute coronary syndromes taking atorvastatin versus other statin therapies. , 2003, The American journal of cardiology.

[4]  B. Giusti,et al.  Relation of cytochrome P450 2C19 loss-of-function polymorphism to occurrence of drug-eluting coronary stent thrombosis. , 2009, The American journal of cardiology.

[5]  Deepak L. Bhatt,et al.  ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. , 2008, Circulation.

[6]  A. Kastrati,et al.  Antiplatelet effects of a 600 mg loading dose of clopidogrel are not attenuated in patients receiving atorvastatin or simvastatin for at least 4 weeks prior to coronary artery stenting. , 2004, European heart journal.

[7]  Marie M. Ahlström,et al.  Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. , 2004, Drug metabolism and disposition: the biological fate of chemicals.

[8]  P Michael Ho,et al.  Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. , 2009, JAMA.

[9]  A. Siegbahn,et al.  Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. , 2006, European heart journal.

[10]  Peter C. Austin,et al.  A population-based study of the drug interaction between proton pump inhibitors and clopidogrel , 2009, Canadian Medical Association Journal.

[11]  E. Antman,et al.  Prasugrel Compared With High Loading– and Maintenance–Dose Clopidogrel in Patients With Planned Percutaneous Coronary Intervention: The Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation–Thrombolysis in Myocardial Infarction 44 Trial , 2007, Circulation.

[12]  E. Antman,et al.  Prasugrel versus clopidogrel in patients with acute coronary syndromes. , 2007, The New England journal of medicine.

[13]  K. Winters,et al.  A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation. , 2007, American heart journal.

[14]  S. Steinhubl,et al.  Lack of Adverse Clopidogrel–Atorvastatin Clinical Interaction From Secondary Analysis of a Randomized, Placebo-Controlled Clopidogrel Trial , 2003, Circulation.

[15]  S. Steinhubl,et al.  Abstract 3999: Baseline Proton Pump Inhibitor Use is Associated with Increased Cardiovascular Events With and Without the Use of Clopidogrel in the CREDO Trial , 2008 .

[16]  Dominique Mottier,et al.  Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. , 2008, Journal of the American College of Cardiology.

[17]  Paul B. Watkins,et al.  Atorvastatin Reduces the Ability of Clopidogrel to Inhibit Platelet Aggregation: A New Drug–Drug Interaction , 2003, Circulation.

[18]  B. Jilma,et al.  Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel. , 2009, American heart journal.

[19]  M. Cheitlin.  Cytochrome P450 Genetic Polymorphisms and the Response to Prasugrel: Relationship to Pharmacokinetic, Pharmacodynamic, and Clinical Outcomes , 2010 .

[20]  J. Ferrières,et al.  Genetic determinants of response to clopidogrel and cardiovascular events. , 2009, The New England journal of medicine.

[21]  E. Antman,et al.  Cytochrome p-450 polymorphisms and response to clopidogrel. , 2009, The New England journal of medicine.

[22]  G. Montalescot,et al.  Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study , 2009, The Lancet.

[23]  M. Gilard,et al.  Influence of omeprazol on the antiplatelet action of clopidogrel associated to aspirin , 2006, Journal of thrombosis and haemostasis : JTH.

[24]  M. Hadamitzky,et al.  Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel , 2009, Thrombosis and Haemostasis.